Neurofibromatosis type 2 (NF2) is an autosomal dominant Mendelian tumor predisposition disorder caused by germline pathogenic variants in the tumor suppressor NF2. Meningiomas are the second most common neoplasm in NF2, often occurring in multiple intracranial and spinal locations within the same patient. In this prospective longitudinal study, we assessed volumes and growth rates of ten spinal and ten cranial benign meningiomas in seven NF2 patients that concluded with surgical resection and performed whole-exome sequencing and copy-number variant (CNV) analysis of the tumors. Our comparison of the volume and the growth rate of NF2-associated spinal and cranial meningiomas point to the differences in timing of tumor initiation and/or to the differences in tumor progression (e.g., non-linear, saltatory growth) at these two anatomical locations. Genomic investigation of these tumors revealed that somatic inactivation of NF2 is the principal and perhaps the only driver of tumor initiation; and that tumor progression likely occurs via accumulation of CNVs, rather than point mutations. Results of this study contribute to a better understanding of NF2associated meningiomas clinical behavior and their genetic underpinnings. Neurofibromatosis type 2 (NF2) is a rare hereditary neoplasia syndrome, with an estimated incidence of 1:25,000-1:33,000 1,2. Although the hallmark and primary definitive diagnostic criterion of NF2 is the presence of bilateral vestibular schwannomas, meningiomas are the next most frequently identified tumor in these patients 3,4. It is estimated that 45-58% of NF2 patients harbor intracranial meningiomas and 20% have spinal meningiomas 5-7. Meningiomas in NF2 are typically WHO grade 1, slow-growing, benign tumors. When present, meningiomas in NF2 patients are often multiple, which contributes significantly to morbidity and mortality. Although symptoms are primarily due to the direct mass effect of tumor upon adjacent brain and cranial nerves, tumors may also evoke seizures and obstruct venous outflow causing cerebral edema 6. A case series examining 287 cranial meningiomas from NF2 patients confirmed that similar to their sporadic counterparts, the majority of NF2-associated meningiomas (95.8%) were grade 1 by WHO guidelines. Although only 4.2% of total meningiomas were grade 2 or 3, 35% of growing or symptomatic resected meningiomas were grade 2/3. Growth rate was generally slow, although 7.3% of meningiomas examined by MRI analysis displayed an annual volumetric growth rate of 20% or higher 8. The cumulative burden of intracranial meningiomas in NF2 patients results in a 2.51-fold greater risk of mortality when compared to NF2 patients without intracranial meningiomas 9 .